These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29651918)

  • 61. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients.
    Kono T; Ueda T; Takumida M; Furuie H; Hamamoto T; Takeno S; Hirakawa K
    Acta Otolaryngol; 2018 Oct; 138(10):921-925. PubMed ID: 30016902
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
    Svanberg A; Birgegård G
    Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics.
    Jackson K; Letton C; Maldonado A; Bodiford A; Sion A; Hartwell R; Graham A; Bondarenka C; Uber L
    J Oncol Pharm Pract; 2019 Jun; 25(4):847-854. PubMed ID: 29587608
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
    Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM
    Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
    Bodge M; Shillingburg A; Paul S; Biondo L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1111-3. PubMed ID: 24357337
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
    Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
    Chan A; Low XH; Yap KY
    J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Incidence and treatment of chemotherapy-induced nausea and emesis in gastrointestinal cancer].
    Lorenzen S; Spörl S; Lordick F
    Z Gastroenterol; 2014 Aug; 52(8):821-30. PubMed ID: 25111723
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
    Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
    Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
    Adra N; Albany C; Brames MJ; Case-Eads S; Johnson CS; Liu Z; Fausel CA; Breen T; Hanna NH; Hauke RJ; Picus J; Einhorn LH
    Support Care Cancer; 2016 Jul; 24(7):2837-42. PubMed ID: 26838019
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells.
    Eisenberg S; Wickline M; Linenberger M; Gooley T; Holmberg L
    Oncol Nurs Forum; 2013 May; 40(3):285-92. PubMed ID: 23615140
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
    Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
    J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
    Navari RM
    Future Oncol; 2019 Jan; 15(3):241-255. PubMed ID: 30304952
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
    Scher CS; Amar D; McDowall RH; Barst SM
    Can J Anaesth; 1992 Feb; 39(2):170-2. PubMed ID: 1544199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.